

Sage Therapeutics (SAGE : US\$60.53)

Sage Therapeutics continues uptrend, soars 56% and in top 5% of the market

Sage Therapeutics Inc., NASDAQ's 7th largest Healthcare-Products company by market cap, soared US\$21.83 (or 56.4%) year to date in 2015 to close at US\$60.53. This means the stock is among the top 5% of NASDAQ-listed stocks in 2015. Compared with the NASDAQ-100 Index which has risen 4.4% YTD, this is a relative price increase of 52%. The volume YTD has been 1.6 times the average trading of 134,041 shares. In 2015 the market cap has jumped US\$561.3 million.

Introduction with Trends

We are currently bullish on this stock in the short-term based on technical indicators, but are more bearish in the long-term based on fundamental metrics

What makes us most bullish on the stock is the following:

- Its Moving Average Convergence Divergence indicators are rising, with its 12-day EMA higher than its 26-day EMA.
- The price to 200-day MAP ratio is 1.07, a bullish indicator.
- In the last three months the number of rises outnumbered falls 37:26 or 1.4:1.
- It is beating 96% of the market the past 6 months.

However, there are some reasons why we remain bearish on the stock for the long-term:

- The Q Ratio, defined by James Tobin as MCap divided by Total Assets, is 12. Compared with the rest of the market the stock is overvalued and ranks in the bottom 2% of stocks by value of Q Ratio.

Stock Summary

Sector	Healthcare-Products
Market Cap	US\$1.6 billion
Shares Outstanding	25,711,926
ISIN	US78667J1088
Relative Strength (3 mo)	96

Financial Summary

Year ended	Dec 2014	Dec 2013	Dec 2012
Net (USD M)	(36.1)	(18.3)	(9.6)
EPS (USD)	(1.67)	(12.26)	(8.62)

MCap: A Historical Perspective

	Share Price (USD)	Market Cap (US\$)
Last	60.5	1.6 billion

Analysis

Bullish Signals

- Rises to Falls: In the last three months the number of rises outnumbered falls 37:26 or 1.4:1.
- In the NASDAQ market of 2,406 stocks and 1 unit traded today, the stock has a 6-month relative strength of 96 which means it is beating 96% of the market.
- A price rise combined with a high relative strength is a bullish signal.
- The Moving Average Convergence Divergence (MACD) indicator of 12-day Exponential Moving Average (EMA) of 55.1 minus the 26-day EMA of 51.64 is positive suggesting a bullish signal. Both the 12-day EMA as well as the 26-day EMA are rising, another bullish signal.
- The Price/MAP of 1.07 for SAGE is higher than the Price/MAP for the NASDAQ-100 Index of 0.9.
- The price to 200-day MAP ratio is 1.07, a bullish indicator. In the past 200 days this ratio has exceeded 1.07, 11 times suggesting further upside. The 50-day MAP of US\$66.38 is higher than the 200-day MAP of US\$56.77, a bullish indicator. The 200-day MAP has increased to US\$56.77. An increase is another bullish indicator.
- The current short volume is 0.4 times its own historical average of 0.2%. It plummeted 23.6% from the previous day, plummeted 70.2% from a week ago and plummeted 79.2% from a month ago, a significant bullish indicator.

Other Bullish Signals:

Also, the following criteria set by Benjamin Graham:

- "Current ratio of two or more"; current assets are 16.6 times current liabilities.

Bullish Indicators and Rank in Market:

Description	Value	Rank In Market
Relative Strength (6M)	96	In Top 5%
%Prem To Vol Wtd Price	13.8	In Top 8%
MCap	US\$1.6 billion	In Top Quartile

Bearish Signals

- The price is at a premium of 13.8% to the 1-month volume weighted average price of US\$53.18. Given that this premium has been under 13.8% one hundred sixty-eight times and over 13.8% seventeen times in the last year, the downside:upside probability is estimated at 168:17 or 9.9:1.
- The Stochastic indicator of 89.6 has broken through the overbought line of 80; the stock is also overbought according to the Williams % R indicator of -14.1.

Overvaluation:

- The Q Ratio, defined by James Tobin as MCap divided by Total Assets, is 12. Compared with the rest of the market the stock is overvalued and ranks in the bottom 2% of stocks by value of Q Ratio.

Other Bearish Signals:

The stock has a score of merely 1 out of 9 set by Joseph Piotroski [pass mark ≥ 5]:

Improvement in current ratio from 3.6 to 16.6.

Bearish Indicators and Rank in Market:

Description	Value	Rank In Market
Price to Book Value	12.8	In Bottom 8%


Note

Neutral Indicators and Rank in Market:


Description	Value	Rank In Market
Turnover in Quarter	US\$769.1 million	In 2nd Quartile

Analysis (continued)

Short Selling to Mcap



Turnover Rate & Turnover Period




Insider Trades




Trailing 3 months

Turnover	US\$769.1 million
Volume	15,776,953
Volume Index (1 is avg)	1.9


YTD Comparison Stock Sector Index




Relative Strength



Weekly Price Volume Dynamics (Last 12 Weeks)



Stock v Index (Trailing Year)



Price/Moving Average Price [P/MAP]



Peer Group Analysis

Name	Last Price	Relative strength (6-months)	MCap (USD)	PV \$1000 (1 yr)	Revenue (USD)	Net Profit (USD)	Total Assets (USD)
Ultragenyx Pharmaceutical	US\$62.59	80	2.2B	1,384		(64.6M)	198M
Cempra	US\$38.19	100	1.7B	4,274	15.2M	(61.6M)	105.3M
Radius Health	US\$41.68	99	1.6B	0		(71.5M)	108.4M
Sage Therapeutics	US\$60.53	96	1.6B	0		(36.1M)	129.7M
Relypsa	US\$35.83	96	1.5B	1,590		(73.8M)	106M
HealthEquity	US\$24.50	74	1.3B	0	87.9M	12.1M	158.8M
Karyopharm Therapeutics	US\$33.0	32	1.2B	1,019	229,000	(75.8M)	220.3M

Recent Analyst Recommendations

Date	Brokerage	Action	Past Rating	Current Rating	Prev Target	Price Target
06-Apr-2015	JPMorgan Chase & Co.	Boost Price Target	-	Overweight	51	58
02-Apr-2015	Canaccord Genuity	Set Price Target	-	Buy	-	58
02-Apr-2015	JPMorgan Chase & Co.	Reiterated Rating	-	Buy	-	-
23-Mar-2015	Vetr Inc.	Upgrade	Strong Sell	Sell	-	50.68
20-Mar-2015	William Blair	Initiated Coverage	-	Outperform	-	75
19-Mar-2015	Vetr Inc.	Downgrade	Sell	Strong Sell	-	46.62
27-Feb-2015	Canaccord Genuity	Reiterated Rating	-	Buy	-	58
24-Feb-2015	Vetr Inc.	Upgrade	Sell	Hold	-	46.12
23-Feb-2015	Vetr Inc.	Downgrade	Hold	Sell	-	46
27-Jan-2015	SunTrust	Initiated Coverage	-	Buy	-	67

Reported Selling by Insiders

Insider	Date	Transaction Type	No. of Shares	Price, US\$	Value, US\$
Paul Steven M	Apr 01, 2015	Sold	20,000	48.51	970,200
Kanes Stephen	Mar 25, 2015	Sold	5,400	51.49	278,046
Kanes Stephen	Jan 26, 2015	Sold	6,000	37.29	223,717

Company Overview

Activities

Sage Therapeutics Inc. develops treatments for central nervous system disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Sage Therapeutics operates in the United States.

Further details can be found at
www.sagerx.com.

Economic Sector	Healthcare
-----------------	------------

Regulatory Announcements

Key Developments

April 14: SAGE Therapeutics Announces Pricing of Public Offering of Common Stock

[News Story] CAMBRIDGE, Mass., April 14, 2015 SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 2,285,714 shares of its common stock at a public offering price of \$52.50 per share, before underwriting discounts.

[For more details click here.](#)

Key Developments

April 13: SAGE Therapeutics Announces Proposed Public Offering of Common Stock

[News Story]

SAGE Therapeutics (Nasdaq:SAGE) today announced that it has commenced an underwritten public offering of \$100 million of shares of its common stock. All of the shares in the offering are to be sold by SAGE. SAGE intends to grant the underwriters a 30-day option to purchase up to an additional \$15 million of shares of common stock at the public offering price, less the underwriting discount.

J.P.

[For more details click here.](#)

Conferences/Exhibitions

April 10: Events Calendar: SAGE Therapeutics Announces Presentations at Upcoming Scientific Conferences

CAMBRIDGE, Mass., April 9, 2015 SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced oral and poster presentations at three upcoming scientific conferences. Presentations include data from the Phase 1/2 clinical trial of SAGE-547 as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE), a rare and life-threatening seizure disorder for which there are no approved therapies, and preclinical data for SAGE-689, being developed as an adjunctive intravenous second-line therapy for the treatment of refractory status epilepticus.

Following is a schedule of SAGE's presentations: 5th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Title: SAGE 547, for Super-Refractory Status Epilepticus; a Clinical Update Date: Saturday, April 11, 2015 Time: 6:30 a.m.

[For more details click here.](#)

April 02: SAGE Therapeutics Announces Positive End-of-Phase 2 Meeting With FDA and Planned Initiation of SAGE-547 Global Phase 3 Trial in Mid-2015

[News Story]

SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced details of its planned SAGE-547 global Phase 3 development program for the treatment of patients with super-refractory status epilepticus (SRSE).

[For more details click here.](#)

Financial Results

February 28: SAGE Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results

[News Story] CAMBRIDGE, Mass., Feb. 27, 2015 -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2014.

"SAGE had a remarkable year in 2014 with the achievement of several clinical and corporate milestones, including significant progress in the development of our lead molecule, SAGE-547, successful completion of our initial public offering, and essential additions to our leadership team and board," said Jeff Jonas, M.D., chief executive officer of SAGE.

[For more details click here.](#)

Company Overview (continued)

February 13: SAGE Therapeutics Appoints New Vice Presidents to Lead Key Organizational Functions

[News Story] CAMBRIDGE, Mass., Feb. 13, 2015- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the appointment of Amy Schacterle, Ph.D., as vice president of regulatory affairs and quality assurance and Erin Lanciani as vice president of human resources.

"The additions of our new vice president of regulatory affairs and quality assurance and vice president of human resources are a testament to SAGE's continued growth and maturity as an organization," said Jeff Jonas, M.D., chief executive officer of SAGE Therapeutics.

Conferences/Exhibitions

January 28: SAGE Therapeutics Announces Participation in February Conferences

[News Story] CAMBRIDGE, Mass., Jan. 28, 2015 SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced management will participate in three upcoming healthcare investor conferences, as follows:

Canaccord Genuity Rare Disease, BioPharma 1x1 Day on Tuesday, Feb.

[For more details click here.](#)

8-K people news

September 16: Sage Therapeutics elects Michael F. Cola as director 17 September 2014

Sage Therapeutics has elected Michael F. Cola as Director as on Sep 11, 2014.

8-K other news

February 27: Sage Therapeutics: Results of Operations and Financial Condition

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1597553_000119312515069916_0001193125-15-069916.txt

Source: 8-K United States Securities and Exchange Commission

January 09: Sage Therapeutics: Other Events

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1597553_000119312515006304_0001193125-15-006304.txt

Source: 8-K United States Securities and Exchange Commission

November 12: Sage Therapeutics: Results of Operations and Financial Condition

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1597553_000119312514407567_0001193125-14-407567.txt

Source: 8-K United States Securities and Exchange Commission

August 14: Sage Therapeutics: Results of Operations and Financial Condition

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1597553_000119312514309099_0001193125-14-309099.txt

Source: 8-K United States Securities and Exchange Commission

July 25: Sage Therapeutics: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1597553_000119312514279676_0001193125-14-279676.txt

Source: 8-K United States Securities and Exchange Commission

Sector Sorting

For Company searches, or for sorting by Stocks and variables, an interactive version of today's Table is available [here](#)

Issued Capital

Based on 25,711,926 issued equity shares the market capitalisation is US\$1.6 billion.


The top sixteen shareholders hold 54.4% of the issued capital leaving a float of 45.6%.

Company Overview (continued)

Top 10 Shareholders

Name of Shareholder	No. of Shares	% Held
Third Rock Ventures LLC	11,681,008	45.43
Ecor1 Capital LLC	491,044	1.91
Orbimed Advisors LLC	412,335	1.6
Deerfield Management Co	262,625	1.02
Vanguard Group Inc	222,745	0.87
Franklin Resources Inc	200,000	0.78
Foresite Capital Management II LLC	144,569	0.56
Stifel Nicolaus & Co Inc \Mo\	100,261	0.39
Sphera Funds Management Ltd.	79,724	0.31
State Street Corp	72,872	0.28
Total	13,667,183	53.16

Top 16 Institutional Holdings



Board and Management

Jeffrey Jonas CEO & Managing Director

Jeffrey Jonas joined SAGE Therapeutics as CEO in 2013 and has more than 20 years of experience on both the scientific and business sides of the pharmaceutical and healthcare industries, particularly in the CNS field. Before joining the SAGE team, Dr. Jonas served as the President of the Regenerative Medicine Division of Shire plc and previously as Senior Vice President of Research and Development, Pharmaceuticals at Shire. Prior to Shire, he served as the Executive Vice President of ISIS Pharmaceuticals, as the Chief Medical Officer and Executive Vice President of Forest Laboratories, Inc. and in senior-level positions at Upjohn Laboratories. Dr. Jonas founded AVAX Technologies, where he served as CEO and President, and SCEPTOR Industries, where he served as Chairman, President and Chief Technology Officer. Earlier in his career, he served as Independent Director at Cara Therapeutics, Inc. and Director of AVAX Technologies. He has published more than 70 scientific papers and chapters, authored more than 100 books, scientific articles and abstracts, and has received numerous awards.

Dr. Jonas received his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard, and then served as Chief Resident in psychopharmacology at McClean Hospital, Harvard Medical School.

Al Robichaud Chief Scientific Officer

Al joined SAGE as CSO in 2011, with more than 20 years of drug discovery experience focused primarily in the neuroscience arena. Most recently, he was Vice President of Chemistry and Pharmacokinetic Sciences at Lundbeck USA, where he was responsible for t

Kimi Iguchi CFO

Kimi Iguchi joined SAGE Therapeutics as CFO in 2013, bringing both financial and operating strength from her senior management experience at Millennium, Biogen and emerging life science companies. Prior to joining SAGE, Ms. Iguchi served as the Chief Operating Officer, North America, for Santhera Pharmaceuticals. Prior to that, she held the role of Vice President of Finance at Cyberkinetics Neurotechnology Systems. Previously, Ms. Iguchi was the Senior Director of Financial Reporting and Analysis at Millennium Pharmaceuticals and the Senior Manager External Reporting at Biogen, Inc. She also worked as a business assurance manager at PricewaterhouseCoopers LLP and started her career in chemistry-related positions at various Boston-based companies. Ms. Iguchi holds a B.A. in chemistry from Drew University and an MBA from Northeastern University.

Steven Paul Director

Steven has had a distinguished career in neuroscience, particularly in CNS drug discovery and development. Steven is the former President of the Lilly Research Laboratories of Eli Lilly and Company and now leads the Helen & Robert Appel Institute for Alzheimer's Research at Weill Cornell Medical College. Prior to his appointment at Weill Cornell, Steven spent 17-years at Eli Lilly, during which time he held several key leadership roles, including Vice President of Neuroscience (CNS) Research and Group Vice President of Discovery Research (all therapeutic areas). In his most recent role, he was responsible for the company's overall research and development efforts helping to expand Lilly's R&D efforts in oncology and biotechnology resulting in a pipeline of approximately 70 new molecular entities. Prior to Lilly, Steven served as Scientific Director of the National Institute of Mental Health. He has also served as Medical Director in the Commissioned Corps of the United States Public Health Service. Steven has been the recipient of many awards and honors and has served on numerous committees and advisory boards. He has also authored or co-authored more than 500 papers and book chapters. Steven is an elected fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences. He is also currently on the board of directors or is a trustee of several organizations, including the Sigma-Aldrich Corporation, Alnylam Pharmaceuticals, Allen Institute for Brain Science, The Mind Research Network and the Foundation for the NIH. Dr. Paul has also served as a member of the National Institute of General Medical Sciences (NIGMS) Advisory Council and was appointed by the Secretary of the Department of Health and Human Services (HHS) as a member of the advisory committee to the Director of the NIH from 2001-2006. Steven is currently a member of the National Advisory Mental Health Council, NIMH, and is board certified by the American Board of Psychiatry and Neurology.

Steve Kanés Chief Medical Officer

Steve joined SAGE as CMO in 2013. Steve is a former practicing psychiatrist and previously served as the Executive Director/Therapeutic Area Clinical Director for the inflammation, neuroscience and respiratory GMED division of AstraZeneca Pharmaceuticals. At AstraZeneca, he also served as the Chair of the Neuroscience Safety Knowledge Group. During his time at AstraZeneca, Steve served as the Medical Science Senior Director for the neuroscience established brands and emerging anesthesia group product team and in other positions of increasing responsibility in the neuroscience discovery medicine, early and late development groups. Prior to joining AstraZeneca, he was a faculty member in the psychiatry department at the University of Pennsylvania School of Medicine, where he continues to serve as an adjunct assistant professor of psychiatry. Steve has authored or co-authored more than 30 peer-reviewed publications. He serves as an ad hoc reviewer for the journals Neuropsychopharmacology, American Journal of Medical Genetics and Biological Psychiatry.

Board and Management (continued)

Michael F. Cola Director

Mr. Cola served as President of Specialty Pharmaceuticals at Shire plc, a global specialty pharmaceutical company, from 2007 until April 2012. He joined Shire in 2005 as Executive Vice President of Global Therapeutic Business Units and Portfolio Management. Prior to joining Shire, he was with Safeguard Scientifics, Inc., a growth capital provider to life sciences and technology companies, where he served as President of the Life Sciences Group. Mr. Cola received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. He serves on the Board of Directors of Vanda Pharmaceuticals Inc., NuPathe Inc. and Pennsylvania BIO, the statewide association representing the bioscience community. He also currently serves as Chairman of the Board of Governors of the Boys & Girls Clubs of Philadelphia.

Creation of shareholder value in Sage Therapeutics:

Since appointment as Director: The present value of USD1,000 invested on the appointment date of September 11, 2014 at close price of US\$29.80 is US\$2,031, for a capital gain of US\$1,031.

Financial Results (Annual)

31 December, 2014

Annual Report for the year ended December 31, 2014

year-on-year comparisons with previous corresponding period

Favourable Changes

- EPS continued to be negative like in the previous year
- However, there was an improvement from \$US-12.26 in the previous year to \$US-1.67
- Working capital to total assets up 30.8% to 93.4%.

Unfavourable Changes

- Loss of \$US36.1m
- Losses in all of the last 3 years
- Operating cash flow is negative.

Major Common Size Ratios

- Total current assets to total assets up from 98.5% to 99.3%
- Cash to total assets up from 94.5% to 98.5%
- Fixed assets to total assets down from 1.0% to 0.1%.

INCOME STATEMENT

Currency in Thousand of USD	2014-12-31	2013-12-31	Change %
Operating expenses:			
Research and development	24,100	14,357	Up 67.9
General and administrative	9,710	3,922	Up 147.6
Total operating expenses	33,810	18,279	Up 85.0
Loss from operations	-33,810	-18,279	Deterioration 85.0
Interest income (expense), net	8	1	Up 700.0
Other income (expense), net	-9	-3	Deterioration 200.0
Net loss and comprehensive loss	-33,811	-18,281	Deterioration 85.0
Accretion of redeemable convertible preferred stock to redemption value	-2,294	-7	Deterioration 32,671.4
Net loss attributable to common stockholders	-36,105	-18,288	Deterioration 97.4
Net loss per share attributable to common stockholders-basic and diluted	-167.0c	-1,226.0c	Reduced 86.4
Weighted average number of common shares used in net loss per share attributable to common stockholders-basic and diluted	21,574,347	1,492,288	Up 1,345.7

BALANCE SHEET

Currency in Thousand of USD	2014-12-31	2013-12-31	Change %
Assets			
Current assets:			
Cash and cash equivalents	127,766	8,066	Up 1,484.0
Prepaid expenses and other current assets	1,056	341	Up 209.7
Total current assets	128,822	8,407	Up 1,432.3
Property and equipment, net	163	86	Up 89.5

Financial Results (Annual) (continued)

31 December, 2014

Restricted cash	39	39	Steady
Deferred tax assets	641		
Total assets	129,665	8,532	Up 1,419.7
Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)			
Current liabilities:			
Accounts payable	2,429	1,988	Up 22.2
Accrued expenses	4,687	327	Up 1,333.3
Deferred tax liabilities	641		
Total current liabilities	7,757	2,315	Up 235.1
Other liabilities	23	44	Down 47.7
Total liabilities	7,780	2,359	Up 229.8
Commitments and contingencies			
Redeemable convertible preferred stock (Series A, B and C), 0.0001 par value; no shares and 37,750,000 shares authorized at December31, 2014 and 2013, respectively; no shares and 37,750,000 shares issued and outstanding at December31, 2014 and 2013, respectively; liquidation preference of 0 and 40,663 at December31, 2014 and 2013, respectively		37,709	
Stockholders' equity (deficit):			
Preferred stock, 0.0001 par value; 5,000,000 and no shares authorized at December31, 2014 and 2013, respectively; no shares issued or outstanding at December 31, 2014 and 2013, respectively			
Common stock, 0.0001 par value; 120,000,000 and 66,000,000 shares 3 authorized at December 31, 2014 and 2013, respectively; 25,621,791 and 1,622,761 shares issued and outstanding at December 31, 2014 and 2013, respectively			
Additional paid-in capital	188,727	139	Up 135,674.8
Accumulated deficit	-66,845	-31,675	Deterioration 111.0
Total stockholders' equity (deficit)	121,885	-31,536	Recovery
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	129,665	8,532	Up 1,419.7

CASH FLOW

Currency in Thousand of USD	2014-12-31	2013-12-31	Change %
Cash flows from operating activities			
Net loss	-33,811	-18,281	Deterioration 85.0
Adjustments to reconcile net loss to net cash used in operating activities:			
Stock-based compensation expense	2,512	61	Up 4,018.0
Licensing or consulting fees paid in common stock	127	64	Up 98.4
Depreciation and amortization	51	47	Up 8.5

Financial Results (Annual) (continued)

31 December, 2014

Changes in operating assets and liabilities:			
Prepaid expenses and other current assets	-715	-317	Deterioration 125.6
Accounts payable	441	674	Down 34.6
Accrued expenses	4,374	236	Up 1,753.4
Other liabilities	-21		
Net cash used in operating activities	-27,042	-17,516	Deterioration 54.4
Cash flows from investing activities			
Purchase of property and equipment	-128	-3	Deterioration 4,166.7
Net cash used in investing activities	-128	-3	Deterioration 4,166.7
Cash flows from financing activities			
Proceeds from the issuance of Series A preferred stock, net of issuance costs		22,732	
Proceeds from the issuance of Series B preferred stock, net of 14,970 issuance costs			
Proceeds from the issuance of Series C preferred stock, net of 37,890 issuance costs			
Proceeds from the issuance of common stock and restricted stock, 40 net		51	Down 21.6
Proceeds from initial public offering of common stock, net of 96,255 commissions and underwriting discounts			
Payment of offering costs	-2,285		
Net cash provided by financing activities	146,870	22,783	Up 544.6
Net increase in cash and cash equivalents	119,700	5,264	Up 2,173.9
Cash and cash equivalents at beginning of period	8,066	2,802	Up 187.9
Cash and cash equivalents at end of period	127,766	8,066	Up 1,484.0

PERFORMANCE RATIOS

	2014-12-31	2013-12-31	Change %
Return on Assets (%)	-27.84	-214.35	Reduced 87.0
Total Liabilities to Operating Cash Flow	-0.29	-0.13	Deterioration 113.6
Total Liabilities/Total Assets	0.06	0.28	Down 78.3
Current Ratio	16.61	3.63	

PER SHARE FIGURES

	2014-12-31	2013-12-31	Change %
Cash	US\$5.92	US\$5.41	Up 9.6
Working Capital	US\$5.61	US\$4.08	Up 37.5
Shareholders' Funds	US\$5.65	-2,113.26c	Recovery

Financial Results (Annual) (continued)

31 December, 2014

Total Liabilities	36.06c	US\$1.58	Down 77.2
Total Assets	US\$6.01	US\$5.72	Up 5.1
Net Tangible Assets	US\$5.65	-2,113.26c	Recovery
EPS Final	-167.0c	-1,226.0c	Reduced 86.4

BuySellSignals Financial Research provides equity research on over 48,000 companies listed in more than 90 countries and 120 markets across the world. BuySellSignals believes that every stock has a story to tell and that this story changes every day. To capture this story, BuySellSignals offers the latest pertinent and comprehensive information so that investors can make well-informed investment decisions.

BuySellSignals publishes equity research reports on each stock, sector and index daily to capture the latest market movements and sentiments. BuySellSignals eschews "hot tip" or headline investing in favour of high-quality, ultra-current, targeted technical and fundamental information including specific bullish and bearish signals for each stock. Insights that will guide you to the investments that are hard to find in today's hyperactive mainstream markets.

For further details on definitions and quotations from investing legends, [Click here](#)

Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data from BuySellSignals (AFS Licence 222756) and News Bites Pty Ltd, who provide round the clock data on every Australian stock and sector. Neither BuySellSignals nor News Bites are brokers, and neither have an executing, corporate advisory or investment banking function. BuySellSignals and News Bites Pty Ltd, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. The data is sourced from annual reports and company releases and may not be fully up to date. It should be used as a guide only.
